Pharma and biotech companies face a pivotal next step in addressing the increased complexity of production while balancing mounting cost pressures with the need to ensure product quality, security of supply and regulatory compliance.

Camo Analyticsの買収について

Pharma and biotech companies face a pivotal next step in addressing the increased complexity of production while balancing mounting cost pressures with the need to ensure product quality, security of supply and regulatory compliance. Findings from AspenTech® and Longitude’s recent market survey revealed that digital culture and technology adoption provide a competitive edge – but adoption is slow.

GlaxoSmithKline (GSK) wanted to review the structure of its batch production record and associated workflows as part of a continuous improvement process. Reducing batch review time usually results in faster batch cycle time, meaning higher throughput at the production facility and faster cash-to-cash cycle time. AspenTech was selected for this process due to integration with other solutions, such as Aspen InfoPlus.21® and GSK’s existing plant automation software (DCS). The pilot project was a resounding success, reducing order preparation time by 95% and record review time by over 50%.

Delivering higher levels of profitability and sustainability with Industrial AI. We embed AI into our most widely adopted, industry-leading products and solutions, and empower data scientists to collaborate with domain experts to enrich models.